Senores Pharmaceuticals Limited - IPO
MAINBOARDSenores Pharmaceuticals Stock Price
Senores Pharmaceuticals IPO Details
Senores Pharmaceuticals IPO Subscription
Senores Pharmaceuticals IPO Application Wise Breakup (Approx)
Senores Pharmaceuticals IPO Dates
- 20 Dec 2024Opening dateOPD
- 24 Dec 2024Closing dateCOD
- 26 Dec 2024Basis of AllotmentBOA
- 27 Dec 2024Initiation of RefundsIOR
- 27 Dec 2024Credit of SharesCOS
- 30 Dec 2024Listing dateLID
Senores Pharmaceuticals IPO Lot Size
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retain Minimum | 1 | 38 | ₹14,858 |
| Retain Maximum | 13 | 494 | ₹193,154 |
| SHNI Minimum | 14 | 532 | ₹208,012 |
| SHNI Maximum | 67 | 2546 | ₹995,486 |
| BHNI Minimum | 68 | 2584 | ₹1,010,344 |
Senores Pharmaceuticals IPO Reservation
Promoter Holding
Senores Pharmaceuticals IPO Valuations
Senores Pharmaceuticals Limited Financial Information
| Period Ended | 30 Sep 2024 | 31 Mar 2024 | 31 Mar 2023 | 31 Mar 2022 | ||||||||||||||||||||||||||||||||||||
| Assets | 678.08 | 621.88 | 131.05 | 59.15 | ||||||||||||||||||||||||||||||||||||
| Revenue | 183.35 | 217.34 | 39.02 | 14.63 | ||||||||||||||||||||||||||||||||||||
| Profit After Tax | 23.94 | 32.71 | 8.43 | 0.99 | ||||||||||||||||||||||||||||||||||||
| Net Worth | 319.06 | 231.71 | 45.5 | 36.59 | ||||||||||||||||||||||||||||||||||||
| Reserves and Surplus | 263.36 | 175.94 | 35.25 | 25.37 | ||||||||||||||||||||||||||||||||||||
| Total Borrowing | 242.03 | 248.38 | 60.76 | 14.21 | ||||||||||||||||||||||||||||||||||||
| Amount in ₹ Crore | ||||||||||||||||||||||||||||||||||||||||
About Senores Pharmaceuticals IPO
Incorporated in December 2017, Senores Pharmaceuticals Limited develops and manufactures a range of pharmaceutical products primarily for the regulated markets of the US, Canada, and the UK, while also serving emerging markets.
The company's product portfolio consists of Amphetamine Sulfate Tablets, Hydroxychloroquine Sulfate Tablets, Ketoconazole Tablets, Butalbital, Acetaminophen and Caffeine Capsules, Mexiletine Hydrochloride Capsules, Ketorolac Tromethamine Tablets, Diclofenac Potassium Tablets, Diclofenac Potassium Tablets, Nicardipine Hydrochloride Capsules, Escitalopram Tablets, Prochlorperazine Maleate Tablets USP, Terazosin Capsules USP, Morphine Sulfate Tablets, Methadone Hydrochloride Tablets, Cyclobenzaprine Hydrochloride Tablets, Irbesartan Tablets, Risperidone Tablets Topiramate Capsules, and Ivermectin Tablets for regulated markets.
As of September 30, 2024, the company has launched 55 products in key therapeutic areas, including antibiotics and anti-fungal treatments. They have established partnerships with distributors and hospitals across several states in India.
As of September 30, 2024, the company operates three dedicated R&D facilities in India and the US.
The company operates in Emerging Markets across 43 countries and manufactures critical care injectables and APIs.
The company's manufacturing unit is situated in Ahmedabad, Gujrat.
Competitive Strength
- The company serves the US, Canada, and the UK regulated markets with its US FDA-approved manufacturing facility.
- A unique product portfolio tailored for regulated markets developed in a brief period.
- Long-term marketing agreements with pharmaceutical companies in the US, Canada, and the United Kingdom regulated markets.
-
Presence in the Emerging Markets with a product portfolio, including speciality or complex products.
- Robust R&D capabilities driving our differentiated portfolio of products.
- Experieced Management Team
Strength Of Senores Pharmaceuticals IPO
1. Ability to cater to the Regulated Markets of US, Canada and the United Kingdom through our US FDA approved formulation manufacturing facility in the US.
2. Distinct niche product portfolio built in a short span for Regulated Markets of US, Canada and the United Kingdom.
3. Long-term marketing arrangements with pharmaceutical companies in the Regulated Markets, US, Canada and the United Kingdom.
4. Presence in the Emerging Markets with a product portfolio, including specialty or complex products.
5. R&D capabilities driving our differentiated portfolio of products.
6. Professional management teams for our diverse business verticals.
Risk Of Senores Pharmaceuticals IPO
1. Our business is dependent on the sale of our products through third party marketing partners and distributors. The loss of one or more marketing partners or distributors, the deterioration of their financial condition or prospects, or a reduction in their demand for our products or our inability to maintain and increase the number of our arrangements for the marketing and distribution of our products could adversely affect our business, results of operations, financial conditions and cash flows.
2. Our business is dependent on the sale of our products and continued growth of the Regulated Markets. Decrease in market growth for our product or failure to respond to change in market conditions could adversely affect our business, results of operations, financial conditions and cash flows.
3. Failure to comply with the quality standards and technical specifications prescribed by our customers may lead to loss of business from such customers and could negatively impact our business, results of operations and financial condition, including cancellation of existing and future orders which may expose us to warranty claims.
4. We derive a part of our revenue from few customers. If one or more of such customers choose not to source their requirements from us or to terminate our contracts or purchase orders, our business, cash flows, financial condition and results of operations may be adversely affected.
5. We have had negative cash flows from operating activities in the last three Fiscal years and may continue to have negative cash flows in the future which could have an impact on our business and operations.
6. The pharmaceutical market is subject to regulation and failures to comply with the existing and future regulatory requirements in any pharmaceutical market could expose us to litigation or other liabilities, which could adversely affect our reputation, business, financial condition and results of operations. There have been instances in the past where our drugs failed to meet standards prescribed under applicable law and action was taken against us by regulatory authorities.
7. We derive a major portion of our revenue from our operations in the United States. A reduction in demand for our products in these regions could adversely affect our business, results of operations, financial conditions and cash flows.
8. Any manufacturing or quality control problems may damage our reputation for high quality production and expose us to potential litigation or other liabilities, which would negatively impact our business, prospects, results of operations and financial condition.
9. Some of our Directors and Promoters may have interest in entities, which are in businesses similar to ours and this may result in conflict of interest with us. Further, certain of our Promoter Group, Subsidiaries and Group Companies are in the same line of business as us, which may result in a conflict of interest.
10. The erstwhile statutory auditors of our Company have issued a qualified opinion in connection with their audit report for Fiscal 2022.
Objectives Senores Pharmaceuticals IPO
- Investment in one of the Subsidiaries, Havix Group, Inc. d/b/aAavis Pharmaceuticals(“Havix”), to fund capital expenditure requirements for setting up a manufacturing facility for the production of sterile injections in the Atlanta Facility.
- Repayment/pre-payment, in full or in part, of certain borrowings availed by the Company.
- Investment in the Subsidiary, namely, Havix, for re-payment/pre-payment in whole or part of certain borrowings availed by such Subsidiary.
- Funding the working capital requirements of the Company.
- Investment in the Subsidiaries, namely, Senores Pharmaceuticals Inc. (“SPI”)and Ratnatris Pharmaceutical Private Limited (“Ratnatris”), to fund their working capital requirements.
- Funding inorganic growth through acquisition and other strategic initiatives and general corporate purposes.
Company Contact Details
Senores Pharmaceuticals Limited
1101 to 1103, 11th floor,
South Tower, ONE 42 oppositeJayantilal Park,
Ambali Bopal Road, Ahmedabad,-380054
Phone: +91-79-29999857
Email: cs@senorespharma.com
Website: https://senorespharma.com/
Registrar Contact Details
Lead Mangers
Nuvama Wealth Management Limited
Equirus Capital Private Limited
Ambit Private Limited